Save up -80% on Buprenorphine

Note: this is a drug discount program, not an insurance plan.
RX BIN: 015558RX PCN: HTGroup ID: DDN6600Card Holder ID: DDN6600
Pharmacists and Patients support.

2019 Price of Suboxone

$43.9614 sublingual tablets/8 mg
price without discount in nearest pharmacy. Price may vary.

Claim your free Buprenorphine discount card

We offer free Suboxone coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Buprenorphine every time. What are you waiting for? Claim your prescription drug card now!

Walgreens pharmacy
Walgreens pharmacy
CVS pharmacy
CVS pharmacy
Walmart pharmacy
Walmart pharmacy
Ride AID pharmacy
Ride AID pharmacy
CVS Target pharmacy
CVS Target pharmacy
Kroger pharmacy
Kroger pharmacy

Get your Prescription


It’s safe and free


Buy drugs in pharmacy

save money

Save money each time

Buprenorphine volume of distribution

Buprenorphine is very lipophillic and is thus highly distributed. The estimated volume of distribution is 188 – 335 L when given intravenously. It is able to cross into the placenta and breast milk.

RX Prescription
Ask Your therapeut before taking any drugs.

About RX24Drugs

2018 Statistics

discount card

Discount Cards 16,000+


Clients Benefit 29%


Total savings $4,735,080

What is Buprenorphine

Buprenorphine is a derivative of the opioid alkaloid thebaine that is a more potent (25 – 40 times) and longer lasting analgesic than morphine. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.

Buprenorphine mechanism of action

Buprenorphine’s analgesic effect is due to partial agonist activity at mu-opioid receptors. Buprenorphine is also a kappa-opioid receptor antagonist. The partial agonist activity means that opioid receptor antagonists (e.g., an antidote such as naloxone) only partially reverse the effects of buprenorphine. The binding to the mu and kappa receptors results in hyperpolarization and reduced neuronal excitability. Furthermore, buprenorphine slowly dissociates from its receptor. This observation would account for the longer duration of action compared to morphine, the unpredictability of its reversal by opioid antagonists, and its low level of manifest physical dependence. Its receptor fixation half life is 40 minutes which is significantly longer than morphine (milliseconds).

Dosage forms of Buprenorphine

Filmbuccal150 ug/1
Filmbuccal300 ug/1
Filmbuccal450 ug/1

Prescription Generics


International Brands

Act Buprenorphine/naloxone


(-)-Buprenorphine ()-buprenorphine


Actavis Pharma Company

CAS number






Affected organisms

Humans and other mammals

Indication of Buprenorphine

For the treatment of moderate to severe pain, peri-operative analgesia, and opioid dependence.

Toxicity of Buprenorphine

Manifestations of acute overdose include pinpoint pupils, sedation, hypotension, respiratory depression and death.

RX24 Drugs Disclaimer: consult your healthcare provider before buying a Buprenorphine on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.

Get lower price on Buprenorphine now!

What is Suboxone?

Subutex began to be used in Sweden about seven years ago for the treatment of opiate addiction. Methadone and subutex (active ingredient – buprenorphine), in combination with psychosocial therapy, have documented good results for some drug addicts in the form of a reduction in deaths and a generally more healthy and socially stable lifestyle without crime and drugs.

Suboxone has the same effect as Subutex, however, in addition to buprenorphine, it contains naloxone in order to block signals to the central nervous system in case the drug is administered intravenously. Thus, the effect of “ecstasy” does not occur. The manufacturers, the medical company Schering-Plow, hopes that it is precisely this lack of the effect of “ecstasy” that will make the suboxon “uninteresting” for the black market.

However, no mass prescribing of the drug to drug addicts or a reduction in the requirements for participants in replacement therapy programs is expected. The Swedish Department of Social Welfare believes that those who are not addicted to opiates may become dependent on Suboxone.